The DOI matches its Crossref record; 49 of the 52 references it cites were found in a registry or an index, and 2 are not checked yet.
Cross-reactive memory T cells and herd immunity to SARS-CoV-2
Open accessAbstract
Immunity is a multifaceted phenomenon. For T cell-mediated memory responses to SARS-CoV-2, it is relevant to consider their impact both on COVID-19 disease severity and on viral spread in a population. Here, we reflect on the immunological and epidemiological aspects and implications of pre-existing cross-reactive immune memory to SARS-CoV-2, which largely originates from previous exposure to circulating common cold coronaviruses. We propose four immunological scenarios for the impact of cross-reactive CD4+ memory T cells on COVID-19 severity and viral transmission. For each scenario, we discuss its implications for the dynamics of herd immunity and on projections of the global impact of SARS-CoV-2 on the human population, and assess its plausibility. In sum, we argue that key potential impacts of cross-reactive T cell memory are already incorporated into epidemiological models based on data of transmission dynamics, particularly with regard to their implications for herd immunity. The implications of immunological processes on other aspects of SARS-CoV-2 epidemiology are worthy of future study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“lymphocytes from 20% to 50% of unexposed donors display significant reactivity to SARS-CoV-2 Ag peptide pools (Figure 6).”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [111]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This cross-reactivity largely originates from previous exposure to circulating common cold coronaviruses [110-116].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [111]
In the citing paper
“It is possible that cross-protection via adaptive immune responses against endemic coronaviruses might be in part responsible for mild disease courses in younger individuals (Lipsitch et al., 2020).”
From COVID-19 and the human innate immune system (2021) · cites this paper as Lipsitch et al., 2020
In the citing paper
“at least some individuals are low or negative to commercial IgG assays, while retaining detectable SARS-CoV-2 CD4+ T cells. Current estimates are these individuals represent 1%–10% of PCR-confirmed SARS-CoV-2 infections (Gudbjartsson et al., 2020; Lipsitch et al., 2020; Nelde et al., 2021; Schwarzkopf et al., 2021; Sekine et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Lipsitch et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Héry-Arnaud, G., Berre, R. L., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 5,008
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,300
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Self-citationClinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611
Self-citationSuperspreading and the effect of individual variation on disease emergence
Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E., & Getz, W. M. (2005) · Nature · doi:10.1038/nature04153 · Cited by 2,514
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790
Self-citationRobust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Cited by
Sorted by citations
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
Self-citationChen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881
COVID-19 and the human innate immune system
Schultze, J. L., & Aschenbrenner, A. C. (2021) · Cell · doi:10.1016/j.cell.2021.02.029 · Cited by 714
“It is possible that cross-protection via adaptive immune responses against endemic coronaviruses might be in part responsible for mild disease courses in younger individuals (Lipsitch et al., 2020).”
BackgroundTarke, A., Sidney, J., Methot, N., Yu, E. D., Zhang, Y., Dan, J. M., Goodwin, B., Rubiro, P., Sutherland, A., Wang, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100355 · Cited by 706
Self-citationImmune determinants of COVID-19 disease presentation and severity
Brodin, P. (2021) · Nature Medicine · doi:10.1038/s41591-020-01202-8 · Cited by 670
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
The first 12 months of COVID-19: a timeline of immunological insights
Carvalho, T., Krammer, F., & Iwasaki, A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00522-1 · Cited by 483
Tali, S. H. S., LeBlanc, J. J., Sadiq, Z., Oyewunmi, O. D., Camargo, C., Nikpour, B., Armanfard, N., Sagan, S. M., & Jahanshahi‐Anbuhi, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00228-20 · Cited by 430
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
Swadling, L., Diniz, M. O., Schmidt, N. M., Amin, O. E., Chandran, A., Shaw, E., Pade, C., Gibbons, J. M., Bert, N. L., Tan, A. T., et al. (2021) · Nature · doi:10.1038/s41586-021-04186-8 · Cited by 398
SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19
Grifoni, A., Sidney, J., Vita, R., Peters, B., Crotty, S., Weiskopf, D., & Sette, A. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.05.010 · Cited by 314
Self-citationT cell response to SARS-CoV-2 infection in humans: A systematic review
Shrotri, M., van Schalkwyk, M. C., Post, N., Eddy, D., Huntley, C., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245532 · Cited by 352
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
(2021) · doi:10.1126/science.abj9853 · Cited by 327
Self-citationCross-reactive CD4 + T cells enhance SARS-CoV-2 immune responses upon infection and vaccination
Loyal, L., Braun, J., Henze, L., Kruse, B., Dingeldey, M., Reimer, U., Kern, F., Schwarz, T., Mangold, M., Unger, C., et al. (2021) · Science · doi:10.1126/science.abh1823 · Cited by 293
Lumley, S., Wei, J., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T. J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab004 · Cited by 281
Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines
Sette, A., & Crotty, S. (2022) · Immunological Reviews · doi:10.1111/imr.13089 · Cited by 270
Self-citationThe germinal centre B cell response to SARS-CoV-2
Laidlaw, B. J., & Ellebedy, A. H. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00657-1 · Cited by 268
Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety
Mascellino, M. T., Timoteo, F. D., Angelis, M. D., & Oliva, A. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s315727 · Cited by 265
A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection
Augusto, D. G., Murdolo, L. D., Chatzileontiadou, D. S. M., Sabatino, J. J., Yusufali, T., Peyser, N. D., Butcher, X., Kizer, K., Guthrie, K., Murray, V., et al. (2023) · Nature · doi:10.1038/s41586-023-06331-x · Cited by 232
Wilk, A. J., Lee, M. J., Wei, B., Parks, B. E., Pi, R., Martínez-Colón, G. J., Ranganath, T., Zhao, N. Q., Taylor, S., Becker, W. R., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210582 · Cited by 214
Activation or exhaustion of CD8+ T cells in patients with COVID-19
Rha, M., & Shin, E. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00750-4 · Cited by 201
T Cell Responses to SARS-CoV-2
Sette, A., Sidney, J., & Crotty, S. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-061120 · Cited by 191
Self-citationRiou, C., Bruyn, E. D., Stek, C. J., Daroowala, R., Goliath, R. T., Abrahams, F., Said-Hartley, Q., Allwood, B., Hsiao, M., Wilkinson, K. A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149125 · Cited by 207
Self-citationImmune signatures underlying post-acute COVID-19 lung sequelae
Cheon, I. S., Li, C., Son, Y. M., Goplen, N., Wu, Y., Cassmann, T. J., Wang, Z., Wei, X., Tang, J., Li, Y., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abk1741 · Cited by 169
Self-citationImmunity to SARS‐CoV‐2 induced by infection or vaccination
Dopico, X. C., Ols, S., Loré, K., & Hedestam, G. B. K. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 172
The known unknowns of T cell immunity to COVID-19
Karlsson, A. C., Humbert, M., & Buggert, M. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe8063 · Cited by 165
T Cell Memory: Understanding COVID-19
Jarjour, N. N., Masopust, D., & Jameson, S. C. (2020) · Immunity · doi:10.1016/j.immuni.2020.12.009 · Cited by 156
Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans
Cagigi, A., & Loré, K. (2021) · Vaccines · doi:10.3390/vaccines9010061 · Cited by 153
Kent, S. J., Khoury, D. S., Reynaldi, A., Juno, J. A., Wheatley, A. K., Stadler, E., John Wherry, E., Triccas, J., Sasson, S. C., Cromer, D., et al. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00716-1 · Cited by 139
Optimal, near-optimal, and robust epidemic control
Morris, D. H., Rossine, F. W., Plotkin, J. B., & Levin, S. A. (2021) · Communications Physics · doi:10.1038/s42005-021-00570-y · Cited by 131
Single-cell immunology of SARS-CoV-2 infection
Tian, Y., Carpp, L. N., Miller, H. E. R., Zager, M. A., Newell, E. W., & Gottardo, R. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01131-y · Cited by 114
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors
Zsichla, L., & Müller, V. (2023) · Viruses · doi:10.3390/v15010175 · Cited by 121
DiPiazza, A. T., Leist, S. R., Abiona, O. M., Moliva, J. I., Werner, A. P., Minai, M., Nagata, B. M., Bock, K. W., Phung, E., Schäfer, A., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.018 · Cited by 92
Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays
Sholukh, A. M., Fiore-Gartland, A. J., Ford, E. S., Miner, M. D., Hou, Y. J., Tse, L. V., Kaiser, H., Zhu, H., Lu, J., Madarampalli, B., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00527-21 · Cited by 119
Wyllie, D., Jones, H. E., Mulchandani, R., Trickey, A., Taylor-Phillips, S., Brooks, T., Charlett, A., Ades, A., EDSAB-HOME investigators, Moore, P., et al. (2020) · doi:10.1101/2020.11.02.20222778 · Cited by 96
Niessl, J., Sekine, T., Lange, J., Kónya, V., Forkel, M., Marić, J., Rao, A., Mazzurana, L., Kokkinou, E., Weigel, W., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abk0894 · Cited by 94
Ssemaganda, A., Nguyen, H. M., Nuhu, F., Jahan, N., Card, C. M., Kiazyk, S. A. K., Severini, G., Keynan, Y., Su, R., Ji, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30913-4 · Cited by 76
Kaur, U., Ojha, B., Pathak, B. K., Singh, A. K., Giri, K. R., Singh, A. K., Das, A., Misra, A., Yadav, A. K., Kansal, S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101038 · Cited by 78
Antunes, R. D. S., Pallikkuth, S., Williams, E., Yu, E. D., Mateus, J., Quiambao, L. G., Wang, E. W., Rawlings, S. A., Stadlbauer, D., Jiang, K., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab176 · Cited by 70
Self-citationNiessl, J., Sekine, T., & Buggert, M. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101505 · Cited by 77
Bertoletti, A., Tan, A. T., & Bert, N. L. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab006 · Cited by 69
Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
Bhattacharya, D. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.004 · Cited by 64
Havervall, S., Ng, H., Falk, A. J., Greilert‐Norin, N., Månberg, A., Marking, U. W., Laurén, I., Gabrielsson, L., Salomonsson, A., Aguilera, K., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13387 · Cited by 63
Shrwani, K. J., Sharma, R. S., Krishnan, M., Jones, T., Neto, M. M., Cantoni, D. M., Temperton, N. J., Dobson, S. L., Subramaniam, K. S., McNamara, P. S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab333 · Cited by 58
Bartolo, L., Afroz, S., Pan, Y., Xu, R., Williams, L., Lin, C.-F., Tanes, C., Bittinger, K. L., Friedman, E. S., Gimotty, P. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn3127 · Cited by 55
Stražar, M., Park, J., Abelin, J. G., Taylor, H. B., Pedersen, T. K., Plichta, D. R., Brown, E., Eraslan, B., Hung, Y.-M., Ortiz, K., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.05.009 · Cited by 56
Comprehensive analysis of SARS‐CoV‐2 antibody dynamics in New Zealand
Whitcombe, A. L., McGregor, R., Craigie, A., James, A., Charlewood, R., Lorenz, N., Dickson, J. M. J. J., Sheen, C. R., Koch, B., Fox‐Lewis, S., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1261 · Cited by 52
Mahajan, S., Kode, V., Bhojak, K., Coral, K., Lee, K. M., Manoharan, M., Ramesh, A., Sudheendra, H., Srivastava, A., Sathian, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92521-4 · Cited by 54
Nel, A. E., & Miller, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.1c01845 · Cited by 50
Ansari, A., Arya, R. K., Sachan, S., Jha, S. N., Kalia, A., Lall, A., Sette, A., Grifoni, A., Weiskopf, D., Coshic, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636768 · Cited by 50
Self-citationImmunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn
Shahgolzari, M., Yavari, A., Arjeini, Y., Miri, S. M., Darabi, A., Nejad, A. S. M., & Keshavarz, M. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101417 · Cited by 50
Echeverría, G. A., Guevara, A. G., Coloma, J., Ruiz, A. M., Vasquez, M. M., Tejera, E., & de Waard, J. H. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.034 · Cited by 49
McNaughton, A. L., Paton, R. S., Edmans, M. D., Youngs, J., Wellens, J., Phalora, P. K., Fyfe, A. J., Belij‐Rammerstorfer, S., Bolton, J. S., Ball, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.156372 · Cited by 46
Saggau, C., Martini, G. R., Rosati, E., Meise, S., Messner, B., Kamps, A.-K., Bekel, N., Gigla, J. B., Rose, R., Voß, M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.003 · Cited by 42
Optimal, near-optimal, and robust epidemic controlPreprint
Morris, D. H. (2021) · OSF Preprints (OSF Preprints) · Cited by 52
Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
Bilich, T., Roerden, M., Maringer, Y., Nelde, A., Heitmann, J. S., Dubbelaar, M. L., Peter, A., Hörber, S., Bauer, J., Rieth, J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0191 · Cited by 41
Peculiarities of the T Cell Immune Response in COVID-19
Kudlay, D. A., Кофиади, И. А., & Khaitov, M. R. (2022) · Vaccines · doi:10.3390/vaccines10020242 · Cited by 43
Optimal, near-optimal, and robust epidemic control
Morris, D. H., Rossine, F. W., Plotkin, J. B., & Levin, S. (2020) · doi:10.31219/osf.io/9gr7q · Cited by 41
Charland, N., Gobeil, P., Pillet, S., Boulay, I., Séguin, A., Makarkov, A. I., Heizer, G., Bhutada, K., Mahmood, A., Trépanier, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00561-2 · Cited by 73
Targets and cross-reactivity of human T cell recognition of common cold coronaviruses
Tarke, A., Zhang, Y., Methot, N., Narowski, T. M., Phillips, E. J., Mallal, S. A., Frazier, A., Filaci, G., Weiskopf, D., Dan, J. M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101088 · Cited by 39
Self-citationNanomedicine: A Diagnostic and Therapeutic Approach to COVID-19
Sharma, A., Kontodimas, K., & Bosmann, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.648005 · Cited by 39
Alefishat, E. A., Jelinek, H. F., Mousa, M., Tay, G. K., & AlSafar, H. S. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.01.007 · Cited by 39
mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship
Giannotta, G., & Giannotta, N. (2021) · Vaccines · doi:10.3390/vaccines9121503 · Cited by 33
Becerra‐Artiles, A., Calvo‐Calle, J. M., Co, M. D. T., Nanaware, P. P., Cruz, J., Weaver, G. C., Lu, L., Forconi, C. S., Finberg, R. W., Moormann, A. M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110952 · Cited by 36
Dyrdak, R., Hodcroft, E. B., Wahlund, M., Neher, R. A., & Albert, J. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104754 · Cited by 34
Nesterenko, P. A., McLaughlin, J., Tsai, B. L., Sojo, G. B., Cheng, D., Zhao, D. Y., Mao, Z., Bangayan, N. J., Obusan, M. B., Su, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110167 · Cited by 33
Zhou, R., To, K. K., Peng, Q., Chan, J. M., Huang, H., Yang, D., Lam, B. H. S., Chuang, V. W., Cai, J., Liu, N., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.720 · Cited by 33
Gouma, S., Weirick, M. E., Bolton, M. J., Arevalo, C. P., Goodwin, E. C., Anderson, E. M., McAllister, C. M., Christensen, S. R., Dunbar, D., Fiore, D., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150449 · Cited by 30
Russo, G. L., Salvatore, V. D., Sgroi, G., Palumbo, G. A. P., Reche, P. A., & Pappalardo, F. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab403 · Cited by 34
Johansson, A. M., Malhotra, U., Kim, Y. G., Gomez, R., Krist, M. P., Wald, A., Koelle, D. M., & Kwok, W. W. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010203 · Cited by 35
Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID
Krishna, B. A., Lim, E. Y., Mactavous, L., Lyons, P., Döffinger, R., Bradley, J. R., Smith, K. G. C., Sinclair, J. H., Matheson, N. J., Lehner, P. J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104129 · Cited by 32
COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology
Neurath, M. F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00480-y · Cited by 30
Lea, A. J., García, A. R., Arevalo, J. M. G., Ayroles, J. F., Buetow, K. H., Cole, S. W., Rodríguez, D. E., Cayuba, M. G., Highland, H. M., Hooper, P. L., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2207544120 · Cited by 29
SARS-CoV-2 Infection in Ivory Coast: A Serosurveillance Survey among Gold Mine Workers
Milleliri, J., Coulibaly, D., Nyobe, B., Rey, J., Lamontagne, F., Hocqueloux, L., Giachè, S., Valéry, A., & Prazuck, T. (2021) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.21-0081 · Cited by 28
Quiros‐Fernandez, I., Poorebrahim, M., Fakhr, E., & Arregui, A. C. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103610 · Cited by 32
Jia, L., Weng, S., Wu, J., Tian, X., Zhang, Y., Wang, X., Wang, J., Yan, D., Wang, W., Fang, F., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2117503 · Cited by 28
Ciucci, T., Vacchio, M. S., Chen, T., Nie, J., Chopp, L. B., McGavern, D. B., Kelly, M. C., & Bosselut, R. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202343 · Cited by 26
Does common cold coronavirus infection protect against severe SARS-CoV-2 disease?
Meyerholz, D. K., & Perlman, S. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci144807 · Cited by 22
Pre-existing T Cell Memory against Zika Virus
Schouest, B., Grifoni, A., Pham, J. W., Mateus, J., Sydney, J., Brien, J. D., Silva, A. D. D., Balmaseda, Á., Harris, E., Sette, A., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00132-21 · Cited by 26
Self-citationPallikkuth, S., Williams, E., Pahwa, R., Hoffer, M. E., & Pahwa, S. G. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.092 · Cited by 25
Jaago, M., Rähni, A., Pupina, N., Pihlak, A., Sadam, H., Tuvikene, J., Avarlaid, A., Planken, A., Planken, M., Haring, L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20849-6 · Cited by 23
Pinotti, F., Wikramaratna, P. S., Obolski, U., Paton, R. S., Damineli, D. S. C., Alcântara, L. C. J., Giovanetti, M., Gupta, S., & Lourenço, J. (2021) · BMC Medicine · doi:10.1186/s12916-020-01887-1 · Cited by 19
Jo, N., Zhang, R., Ueno, H., Yamamoto, T., Weiskopf, D., Nagao, M., Yamanaka, S., & Hamazaki, Y. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.719342 · Cited by 20
Rise and exacerbation of oral lichen planus in the background of SARS-CoV-2 infection
Sood, A., Raghavan, S., Batra, P., Sharma, K., & Talwar, A. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110681 · Cited by 22
Exposed seronegative: Cellular immune responses to SARS-CoV-2 in the absence of seroconversion
Jay, C., Ratcliff, J., Turtle, L. C. W., Goulder, P., & Klenerman, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1092910 · Cited by 22
Coulon, P.-G. A., Prakash, S., Dhanushkodi, N. R., Srivastava, R., Zayou, L., Tifrea, D. F., Edwards, R. A., Figueroa, C. J., Schubl, S. D., Hsieh, L. L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343716 · Cited by 20
Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel
Ng, K. W., Faulkner, N., Wrobel, A. G., Gamblin, S. J., & Kassiotis, G. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101507 · Cited by 19
Клиническая иммунология. Практическое пособие для инфекционистов
Козлов, В. А., Tikhonova, E. P., Савченко, А. А., Кудрявцев, И. В., Андронова, Н. В., Николаевна, А. Е., Головкин, А. С., Демина, Д. В., Здзитовецкий, Д. Э., Калинина, Ю. С., et al. (2021) · doi:10.17513/np.518 · Cited by 20
Peter, L., Wendering, D. J., Schlickeiser, S., Hoffmann, H., Noster, R., Wagner, D. L., Zarrinrad, G., Münch, S., Picht, S., Schulenberg, S., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.02.012 · Cited by 19
Immune response induced by novel coronavirus infection
Sun, Y., Zou, Y., Wang, H., Cui, G., Yu, Z., & Ren, Z. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.988604 · Cited by 20
Wang, C., Yang, S., Duan, L., Du, X., Tao, J., Wang, Y., Yang, J., Lv, Y., Li, J., Zhang, C., et al. (2022) · Virology Journal · doi:10.1186/s12985-022-01957-1 · Cited by 19
The characterization of CD8 + T-cell responses in COVID-19
Yang, Y., Miller, H. I., Byazrova, M. G., Cndotti, F., Benlagha, K., Câmara, N. O. S., Shi, J., Forsman, H. F., Lee, P. P. W., Yang, L., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2287118 · Cited by 21
COVID-19 vaccination strategies depend on the underlying network of social interactions
Herrmann, H. A., & Schwartz, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-03167-1 · Cited by 21
Wong, L.-Y. R., Zheng, J. H., Sariol, A., Lowery, S. A., Meyerholz, D. K., Gallagher, T., & Perlman, S. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102983118 · Cited by 24
Hsieh, L., Grifoni, A., Sidney, J., Shimizu, C., Shike, H., Ramchandar, N., Moreno, E., Tremoulet, A. H., Burns, J. C., & Franco, A. (2021) · European Journal of Immunology · doi:10.1002/eji.202149556 · Cited by 18
Peluso, M. J., Donatelli, J. L., & Henrich, T. J. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.006 · Cited by 18
An efficient immunoassay for the B cell help function of SARS-CoV-2-specific memory CD4+ T cells
Ansari, A., Sachan, S., Jit, B. P., Sharma, A. K., Coshic, P., Sette, A., Weiskopf, D., & Gupta, N. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100224 · Cited by 19
Self-citationCOVID-19: Mechanistic Model of the African Paradox Supports the Central Role of the NF-κB Pathway
Kircheis, R., Schuster, M., & Planz, O. (2021) · Viruses · doi:10.3390/v13091887 · Cited by 18
Kockelbergh, H., Evans, S. C., Deng, T., Clyne, E., Kyriakidou, A., Economou, A., Hoang, K. N. L., Woodmansey, S., Foers, A. D., Fowler, A., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12051222 · Cited by 19
Fujii, S., Yamasaki, S., Iyoda, T., & Shimizu, K. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00239-1 · Cited by 18
Metadata
- Authors
- Lipsitch, M., Grad, Y. H., Sette, A., & Crotty, S.
- Affiliations
- Harvard University (US)
- La Jolla Institute for Immunology (US)
- Corresponding author
- Lipsitch, Marc
- Grad, Yonatan H.
- Sette, Alessandro
- Crotty, Shane
- Venue
- Nature Reviews Immunology
- Published
- 2020-10-06
- Volume
- 20
- Issue
- 11
- Pages
- 709-713
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7537578
- OpenAlex
- W3091791643
- Cited by
- 260
- References
- 48
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 12 · 2023: 29 · 2022: 59 · 2021: 129 · 2020: 9
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (75N9301900065)
- National Institute of Allergy and Infectious Diseases (U19 AI42742, 75N9301900065, AI42742, U19AI142742)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- SARS-CoV-2, cross-reactive T cells, memory CD4+ T cells, herd immunity threshold, COVID-19 severity, common cold coronaviruses, pre-existing immunity, virus transmission, epidemic modeling, COVID-19 pandemic
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Antibodies, Viral, Coronaviridae, Coronaviridae Infections, Cross Reactions, Humans, Immunologic Memory, Pneumonia, Viral, Rhinovirus, Viral Vaccines, CD4-Positive T-Lymphocytes, Coronavirus Infections, Immunity, Herd, Adaptive Immunity, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
